The WIN symposium is a major annual event presenting breakthrough scientific technologies and achievements in personalized cancer medicine, with a special focus on individualized treatment and early diagnosis of cancer.
Register online for this exciting event, or download a registration form here.

This unique event brings together a broad international audience including experts in oncology such as physicians, scientists, cancer researchers, pharmaceutical and biotechnology companies, healthcare organizations and patient advocates from around the World to offer a strategic alliance and vision on personalized medicine in cancer.

The WIN symposium will be discussing the challenges of early diagnosis; optimum ways to select and deliver personalized treatment, and how to translate these concepts into the clinic.  The event will contain oral presentations, poster sessions and an open interactive forum with the invited speakers and attendees.

Sessions will include advanced scientific concepts in personalized medicine and integrated medicine, breakthrough concepts and technological achievements, biomarker discovery and validation, standardization and harmonization needs in biobanking, clinical drug development. Also to be addressed will be the societal needs and challenges of personalized medicine and the need for greater international co-operation to accelerate translation of research discoveries from the bench to the bedside.

“Co-ordinated interaction between academic institutions and biotechnology and pharmaceutical companies will allow rapid validation of breakthrough concepts and technologies, helping to standardize cancer care.” – Professor Richard Schilsky (Co-chair of the WIN SAB, former President of the American Society of Clinical Oncology) This year’s symposium, to be held in the Palais des Congrès, Paris, on July 7-9th 2010, will offer an interactive forum to discuss new approaches, tools and challenges in cancer medicine. Registered attendees are invited to submit a question relating to unmet needs in individualized cancer care for discussion during this session.

“International co-operations, such as those encouraged by this symposium, are crucial to achieving the Consortium goals within the next 5, rather than 20, years.” – Professor Thomas Tursz (Director of the Institut Gustave Roussy)



Also supported by:

antibodies online